Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.

被引：8
|
作者：
Mehmi, Inderjit
Hamid, Omid
Hodi, F. Stephen
Vassalo, Melinda
Malatyali, Saundra
Krishnarajapet, Swathi
O'Donnell, Nan
Castrence, Angeli
Lim, Eunice
Gormley, Jill
Weber, Jeffrey S.
机构：
[1] Angeles Clin & Res Inst, Los Angeles, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] NYU Langone Hlth, Laura & Issac Perlmutter Canc Ctr, New York, NY USA
[4] NYU Langone, Perlmutter Canc Ctr, New York, NY USA
[5] Perlmutter Canc Ctr, New York, NY USA
[6] NYU Langone, New York, NY USA
[7] Angeles Clin & Res Inst Inc, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS9589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9589
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
    Mason, Robert
    Dearden, Helen C.
    Nguyen, Bella
    Soon, Jennifer A.
    Smith, Jessica Louise
    Randhawa, Manreet
    Mant, Andrew
    Warburton, Lydai
    Lo, Serigne
    Meniawy, Tarek
    Guminski, Alexander
    Parente, Phillip
    Ali, Sayed
    Haydon, Andrew
    Long, Georgina V.
    Carlino, Matteo S.
    Millward, Michael
    Atkinson, Victoria G.
    Menzies, Alexander M.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2020, 33 (02) : 358 - 365
  • [2] Metastatic Melanoma Nivolumab plus Ipilimumab is the better First-line Therapy
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8) : 448 - 449
  • [3] First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
    Kozak, K.
    Teterycz, P.
    Galus, L.
    Mackiewicz, J.
    Brandys, P.
    Cybulska-Stopa, B.
    Kempa-Kaminska, N.
    Zietek, M.
    Zubrowska, J.
    Dziura, R.
    Sobczuk, P.
    Czarnecka, A. M.
    Rutkowski, P.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S666 - S666
  • [4] Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
    Paly, Victoria Federico
    Hikichi, Yusuke
    Baker, Timothy
    Itakura, Eijun
    Chandran, Nisha
    Harrison, James
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1542 - 1552
  • [5] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN
    Baker, T. M.
    Paly, V. F.
    Thybo, S.
    Hultberg, M.
    Minacori, R.
    Kotapati, S.
    Sabater, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A730 - A731
  • [6] Nivolumab and ipilimumab therapy for advanced melanoma
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2013, 14 (08): : E298 - E298
  • [7] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Peter L. Quon
    Ying Xiao
    Sonja Sorensen
    Amir Abbas Tahami Monfared
    [J]. PharmacoEconomics - Open, 2019, 3 : 321 - 331
  • [8] Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab
    Kozak, Katarzyna
    Teterycz, Pawel
    Galus, Lukasz
    Mackiewicz, Jacek
    Galwas-Kliber, Katarzyna
    Kaminska-Winciorek, Grazyna
    Brandys, Piotr
    Cybulska-Stopa, Bozena
    Kempa-Kaminska, Natasza
    Zietek, Marcin
    Zubrowska, Justyna
    Dziura, Robert
    Dembinski, Mateusz
    Bereza, Michal
    Czarnecka, Anna Malgorzata
    Rutkowski, Piotr
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Quon, Peter L.
    Xiao, Ying
    Sorensen, Sonja
    Monfared, Amir Abbas Tahami
    [J]. PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 321 - 331
  • [10] Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients
    Dearden, H. C.
    Mason, R.
    Nguyen, B.
    Soon, J. A.
    Smith, J. L.
    Randhawa, M.
    Mant, A.
    Warburton, L.
    Lo, S.
    Meniawy, T.
    Guminski, A.
    Parente, P.
    Ali, S.
    Haydon, A.
    Long, G. V.
    Carlino, M. S.
    Millward, M.
    Atkinson, V. G.
    Menzies, A. M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 448 - 448
12345